Axicabtagene ciloleucel (Yescarta®)

Assessment Status Pre-submission consultation scheduled
HTA ID 22066
Drug Axicabtagene ciloleucel
Brand Yescarta®
Indication For the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
Assessment Process
Rapid review commissioned 27/09/2022
Rapid review completed 10/11/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of axicabtagene ciloleucel compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 30/11/2022